Clinical Trial Detail

NCT ID NCT03745222
Title A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Celgene
Indications

lung non-small cell carcinoma

Therapies

Tislelizumab

Cisplatin + Etoposide + Tislelizumab

Carboplatin + Paclitaxel + Tislelizumab

Cisplatin + Etoposide

Carboplatin + Paclitaxel

Age Groups: senior adult

No variant requirements are available.